Immunome's varegacestat enters EMA review after strong RINGSIDE results, but safety, competition and approval remain key uncertainties.
Immunome has received U.S. Food and Drug Administration acceptance of its New Drug Application for varegacestat, an investigational once-daily oral gamma secretase inhibitor for adults with desmoid tumors. The application is supported by the Phase 3 RINGSIDE trial and carries an April 28, 2027 target action date, placing the targeted oncology company in a defined
Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.
Immunome is set to release pivotal Phase 3 varegacestat data in desmoid tumors. Find out what the RINGSIDE results could change for the field.